The Emeryville Center development program is just one of many projects BioMed has launched in the Golden State since Blackstone purchased the company in an $8 billion deal. Just weeks ago, in September, BioMed saw the fruits of a $92 million investment with the grand opening of the 137,500-square-foot Center for Novel Therapeutics at the University of California San Diego's Science Research Park campus. Earlier this year, the company commenced construction of Phase II of the 1.5 million-square-foot Gateway of Pacific campus in South San Francisco.